Disclosure Policy
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.
Ineligible companies: The ACCME defines an “ineligible company” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition. |
Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. |
Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship. |
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.
Planning/Development Committee
The following have contributed to the development of ATLS 10 courses as indicated below:
Kimberly Joseph, MD, FACS (Live Activity, Modules)
Nothing to disclose
Sharon Henry, MD, FACS (Live Activity, Modules)
Nothing to disclose
John Sutyak, MD, FACS (Modules)
Nothing to disclose
Joe E. Acker III, MD, FACS (Instructor)
Nothing to disclose
Suresh Agarwal, MD, FACS (Modules)
Nothing to disclose
Galinos Bamparas, MD, FACS (Modules)
Nothing to disclose
Karen Brasel, MD, FACS (Live Activity, Modules)
Nothing to disclose
Julie Dunn, MD, FACS (Modules)
Nothing to disclose
Daniel Grabo, MD, FACS (Modules)
Nothing to disclose
Oscar Guillamondegui, MD, FACS (Modules)
Nothing to disclose
Kenji Inaba, MD, FACS (Modules)
Nothing to disclose
Randeep Jawa, MD, FACS (Modules)
Nothing to disclose
Dennis Kim, MD, FACS (Modules)
Nothing to disclose
Stefan Leichtle, MD, FACS (Modules)
Nothing to disclose
Hunter Moore, MD (Modules)
Founder, Thrombo Therapeutics Incorporated
Deborah Paltridge (Instructor)
No disclosures
Travis Polk, MD, FACS (Modules)
Nothing to disclose
Justin Regner, MD (Modules)
Nothing to disclose
Morgan Schellenberg, MD, FACS (Modules)
Nothing to disclose
Kristin Sihler, MD, FACS (Modules)
Nothing to disclose
